In recent years, the Pharma/Biotech industry has undergone radical changes which have increased are understanding of drug discovery and development, however there are still many hurdles that the industry face.
The gap between a laboratory discovery and an approved drug on the market is a decade-long process of laboratory testing, evaluation in animal models and human clinical trials that can cost hundreds of millions. The conference aims to bridge the gaps in approval for drug discovery and development by discussing the latest scientific breakthroughs, exploring novel technologies and approaches that can be used to overcome drug development challenges.
The conference will bring together industry leaders who will highlight future opportunities for novel therapeutic discovery.
Here’s why you should attend:
- Hear AstraZeneca discuss the use of CRISPR/Cas9 Technology in target discovery, hit finding and translational studies
- Novartis optimises the success of phenotyping screening
- Takeda discusses whether translational medicine capable of increasing success rate in pharma
- Gain insights into receptor activation from agonist and antagonist structures with Merck
- AbbVie explores application of enabling chemistry technology to the acceleration of the drug discovery process